

MEETING ABSTRACT

Open Access

Involvement of 5-lipoxygenase/cysteinyl leukotriene receptor 1 in rotenone- and MPP⁺-induced BV2 microglial activation

Yanfang Wang^{1†}, Xiaoyan Zhang^{1†}, Chengtan Li¹, Jianbo Zhao¹, Erqing Wei², Lihui Zhang^{1*}

From 2011 International Conference on Molecular Neurodegeneration
Shanghai, China. 22-24 September 2011

Background

Neuroinflammation plays a prominent role in the pathogenesis of Parkinson's disease (PD), and microglial activation contributes to initiating and maintaining brain inflammation and neuronal death. 5-Lipoxygenase (5-LOX) is a key enzyme catalyzing arachidonic acid to produce cysteinyl leukotrienes (CysLTs). CysLTs are potent proinflammatory mediators, and their actions are mediated by activating CysLT receptors. We recently reported that rotenone time- and concentration-dependently induced 5-LOX translocation into the nuclear envelope (a key event for 5-LOX activation) and cell injury in PC12 cells, and the 5-LOX selective inhibitor zileuton attenuated rotenone-induced 5-LOX activation and cell injury. To determine the role of 5-LOX pathway in microglial-dependent neuroinflammation, we investigated the changes of 5-LOX and CysLT₁ receptor in a cell model of PD induced by specific mitochondrial complex I inhibitors (rotenone or 1-methyl-4-phenylpyridinium (MPP⁺)) in BV2 microglial cells.

Methods

BV2 cells, a murine BV2 microglia cell line, were cultured in media with or without rotenone (0.1, 0.3, 1, 3, 10 nM) or MPP⁺ (0.003, 0.01, 0.03, 0.1, 0.3 μM) for 24 h. The number of microglia was counted. Phagocytotic activity of BV2 cells was evaluated using fluorescent microspheres. Expression and translocation of 5-LOX

and CysLT₁ receptor were detected by immunocytochemical analysis.

Results

The low doses of rotenone (1-10 nM) or MPP⁺ (0.03-0.3 μM) induced cell proliferation and microglial phagocytosis in BV2 cells. The number of BV2 cells was significantly increased after 24 h treatment with 1 nM rotenone or 0.03-0.1 μM MPP⁺. After treatment with 1-10 nM rotenone or 0.01-0.3 μM MPP⁺, phagocytosis was significantly increased in BV2 cells. Furthermore, we found that 5-LOX expression was increased in a time-dependent manner, and 5-LOX was primarily localized in the nuclear envelope and cytoplasm, and a plaque-like distribution was found in the nucleus in rotenone (3 nM)-activated BV2 cells. In addition, MPP⁺ (0.003-0.3 μM) concentration-dependently induced CysLT₁ receptor translocation from cell membrane to the cytoplasm.

Conclusion

These results suggest an involvement of the 5-LOX/CysLT₁ receptor in rotenone- and MPP⁺-induced BV2 microglial activation. The 5-LOX signaling pathway might therefore be a potential therapeutic target for modulating microglial-mediated inflammation of PD.

Acknowledgements

Supported by Zhejiang Provincial Education Department Science Foundation of China (Y200907625), Hangzhou Key Laboratory Research Program of China (20090233T12), and Hangzhou Normal University Science Foundation of China (2010PYj41).

Author details

¹Hangzhou Key Laboratory of Neurobiology and Department of Pharmacology, School of Basic Medicine, Hangzhou Normal University,

* Correspondence: lihuizhang002@sina.com

† Contributed equally

¹Hangzhou Key Laboratory of Neurobiology and Department of Pharmacology, School of Basic Medicine, Hangzhou Normal University, Hangzhou 310036, China

Full list of author information is available at the end of the article

Hangzhou 310036, China. ²Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China.

Published: 7 February 2012

doi:10.1186/1750-1326-7-S1-S24

Cite this article as: Wang *et al.*: Involvement of 5-lipoxygenase/cysteinyl leukotriene receptor 1 in rotenone- and MPP⁺-induced BV2 microglial activation. *Molecular Neurodegeneration* 2012 **7**(Suppl 1):S24.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

